drugset / Trial / NCT04469673
A Study to Evaluate the Safety, Tolerability and Efficacy of Multiple Doses of JS002 in Patients With Hyperlipidemia..
RandomizedSequentialOpen-labelTreatment
Summary
JS002 is a recombinant humanized anti-PCSK9 monoclonal antibody.
Timeline
- Start
- 2019-05-23
- Primary completion
- 2020-05-03
- Completion
- 2020-06-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ongericimab | Monoclonal antibody | — | Subcutaneous |